This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bairey, O. Articles by Rabizadeh, E. Search for Related Content PubMed PubMed Citation Articles by Bairey, O. Articles by Rabizadeh, E.

Bcl-2, Bcl-X, Bax, and Bak Expression in Short- and Long-Lived Patients with Diffuse Large B-Cell Lymphomas¹

Institute of Hematology and Pathology [E. O.] and Felsenstein Medical Research Center [O. B., Y. Z., M. S., E. R.], Rabin Medical Center, Petah Tiqva 49100, Israel, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel [O. B., M. S., E. O.]

Long-term cure is now possible for 50% of all patients with aggressive non-Hodgkin’s lymphoma (NHL). Apoptosis-related proteins play an important role in the chemosensitivity or chemoresistance of tumors. We examined the role of Bcl-2 family proteins in aggressive NHL. We retrospectively selected two groups of patients by clinical outcome: 24 patients with chemoresponsive disease and long survival (median, 88 months); and 20 patients with chemoresistant disease and short survival (median, 8 months). The expression of the apoptosis-regulating proteins, Bcl-2, Bcl-X, Bax, and Bak, in the initial biopsy samples was examined with immunohistochemical methods. Specimens containing >10% immunostained tumor cells were considered immunopositive. An inverse association was found between length of patient survival and expression of Bcl-2, Bcl-X, and Bax. Bcl-2 was expressed in 75% of short-lived patients but in only 42% of the long-lived ones (P = 0.026). Bcl-X expression was also higher in the short-lived patients (40% versus 12.5%; P = 0.036). Unexpectedly, Bax expression was strongly associated with short survival (60% versus 21%; P = 0.008). Several combinations of protein expression, i.e., Bcl-2 with Bax, Bcl-2 with Bcl-X, and Bcl-X with Bax, were different between the groups: a positive expression of these proteins was found in the short-lived patients. Furthermore, a strong association was found between the expression of Bcl-2 and Bcl-X, suggesting that Bcl-X potentiates rather than replaces the effect of Bcl-2 in NHL. In diffuse large B-cell NHL, Bcl-2, Bcl-X, and Bax expression alone or in combination is associated with chemoresistance and short-term survival.

This article has been cited by other articles:

				S. H. Olejniczak, F. J. Hernandez-Ilizaliturri, J. L. Clements, and M. S. Czuczman Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression Clin. Cancer Res., March 1, 2008; 14(5): 1550 - 1560. [Abstract] [Full Text] [PDF]

				S. A.G.M. Cillessen, C. J. Hess, E. Hooijberg, K. C.M. Castricum, P. Kortman, F. Denkers, W. Vos, M. A. van de Wiel, G. J. Schuurhuis, G. J. Ossenkoppele, et al. Inhibition of the Intrinsic Apoptosis Pathway Downstream of Caspase-9 Activation Causes Chemotherapy Resistance in Diffuse Large B-Cell Lymphoma Clin. Cancer Res., December 1, 2007; 13(23): 7012 - 7021. [Abstract] [Full Text] [PDF]

				C. I. van de Wetering and C. M. Knudson Chromosomal Instability and Supernumerary Centrosomes Represent Precursor Defects in a Mouse Model of T-Cell Lymphoma Cancer Res., September 1, 2007; 67(17): 8081 - 8088. [Abstract] [Full Text] [PDF]

				C. J. Hess, J. Berkhof, F. Denkers, G. J. Ossenkoppele, J. P. Schouten, J. J. Oudejans, Q. Waisfisz, and G. J. Schuurhuis Activated Intrinsic Apoptosis Pathway Is a Key Related Prognostic Parameter in Acute Myeloid Leukemia J. Clin. Oncol., April 1, 2007; 25(10): 1209 - 1215. [Abstract] [Full Text] [PDF]

				A. Yu. Denisov, M. S. R. Madiraju, G. Chen, A. Khadir, P. Beauparlant, G. Attardo, G. C. Shore, and K. Gehring Solution Structure of Human BCL-w: MODULATION OF LIGAND BINDING BY THE C-TERMINAL HELIX J. Biol. Chem., May 30, 2003; 278(23): 21124 - 21128. [Abstract] [Full Text] [PDF]

				G. Z. Rassidakis, L. J. Medeiros, T. J. McDonnell, S. Viviani, V. Bonfante, G. Nadali, T. P. Vassilakopoulos, R. Giardini, M. Chilosi, C. Kittas, et al. BAX Expression in Hodgkin and Reed-Sternberg Cells of Hodgkin's Disease: Correlation with Clinical Outcome Clin. Cancer Res., February 1, 2002; 8(2): 488 - 493. [Abstract] [Full Text] [PDF]

				G. Z. Rassidakis, A. H. Sarris, M. Herling, R. J. Ford, F. Cabanillas, T. J. McDonnell, and L. J. Medeiros Differential Expression of BCL-2 Family Proteins in ALK-Positive and ALK-Negative Anaplastic Large Cell Lymphoma of T/Null-Cell Lineage Am. J. Pathol., August 1, 2001; 159(2): 527 - 535. [Abstract] [Full Text]